The Geminex® dual-release technology is a second
generation technology that has evolved from the TIMERx®
technology platform. Its heritage combines maximum dual-release
versatility with the speed to formulate and cost-effectiveness of
the TIMERx technology. Penwest believes the ultimate result of the application of Geminex to Penwest's
product concepts results in superior products with a speed-to-market advantage.
Because Geminex has evolved from the TIMERx technology
platform, it provides many of the same development and clinical benefits
as does TIMERx (see TIMERx section), while also offering additional
benefits when compared to other dual drug delivery technologies.
The additional benefits are the following:
Geminex can improve the therapeutic benefits of drugs and reduce
side effects by delivering two drugs with complementary mechanisms
of action. The technology is particularly effective for disease
states such as diabetes, hypertension, depression, pain, etc.
Accommodates low to high dose drugs.
Accommodates low to high solubility drugs.
Rapid development times which can result in a speed-to-market advantage.
Custom Geminex formulations are made for each drug component to
ensure
maximum therapeutic benefits.
Special equipment is not required; a standard bi-layer press is
all that is
required.
Geminex-based products are more cost-effective than combination
drug
products that are based on the application of multiparticulate
technologies. |
